Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 785479, 15 pages
http://dx.doi.org/10.1155/2014/785479
Review Article

Preclinical and Clinical Effects of Mistletoe against Breast Cancer

1IJN-UTM Cardiovascular Engineering Center, Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, 81310 Skudai, Johor, Malaysia
2Bioprocess Engineering Department, Faculty of Chemical Engineering, Universiti Teknologi Malaysia, 81310 Skudai, Johor, Malaysia

Received 18 March 2014; Revised 6 June 2014; Accepted 18 June 2014; Published 20 July 2014

Academic Editor: Michel Mittelbronn

Copyright © 2014 Mohsen Marvibaigi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., “Cancer incidence and mortality worldwide: IARC cancer base,” GLOBOCAN 2012, vol. 1, no. 11, 2013. View at Google Scholar
  2. American Cancer Society, Global Cancer Facts & Figures, American Cancer Society, Atlanta, Ga, USA, 2nd edition, 2011.
  3. A. Jemal, F. Bray, and J. Ferlay, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. “SEER stat fa ct sheets: breast cancer,” 2011, http://seer.cancer.gov/statfacts/html/breast.html.
  5. J. Prosnitz, R. R. Iglehart, and E. Winer, “Breast cancer,” in Clinical Oncology: A Multidisciplinary Approach for Physicians and Students, pp. 267–299, Saunders, New York, NY, USA, 2001. View at Google Scholar
  6. US Preventive Services Task Force, “Screening for breast cancer,” 2009, http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm.
  7. Canadian Task Force on Preventive Health Care, “Screening for breast cancer,” 2011, http://www.canadiantaskforce.ca/guidelines/2011-breast-cancer/.
  8. K. Sjöval, G. Strömbeck, A. Löfgren, P. O. Bendahl, and B. Gunnars, “Adjuvant radiotherapy of women with breast cancer—information, support and side-effects,” European Journal of Oncology Nursing, vol. 14, no. 2, pp. 147–153, 2010. View at Google Scholar
  9. C. Connor and D. Attai, “Adjuvant endocrine therapy for the surgeon: options, side effects, and their management,” Annals of Surgical Oncology, vol. 20, no. 10, pp. 3188–3193, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Gianni, B. F. Cole, I. Panzini et al., “Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group,” Supportive Care in Cancer, vol. 16, no. 1, pp. 67–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kado, A. Forsyth, P. R. Patel, and J. A. Schwartz, “Dietary supplements and natural products in breast cancer trials,” Frontiers in Bioscience: Elite, vol. 4, no. 1, pp. 546–567, 2012. View at Google Scholar · View at Scopus
  12. P. J. Mansky and D. B. Wallerstedt, “Complementary medicine in palliative care and cancer symptom management,” Cancer Journal, vol. 12, no. 5, pp. 425–431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Beuth, “Evidence-based complementary medicine in breast cancer therapy,” Breast Care, vol. 4, no. 1, pp. 8–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Beuth and R. Moss, Complementary Oncology: Adjunctive Methods in the Treatment of Cancer, Thieme, New York, NY, USA, 2005.
  15. B. Gerber, C. Scholz, T. Reimer, V. Briese, and W. Janni, “Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review,” Breast Cancer Research and Treatment, vol. 95, no. 3, pp. 199–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Navo, J. Phan, C. Vaughan et al., “An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies,” Journal of Clinical Oncology, vol. 22, no. 4, pp. 671–677, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Cui, X. Shu, Y. Gao et al., “Use of complementary and alternative medicine by Chinese women with breast cancer,” Breast Cancer Research and Treatment, vol. 85, no. 3, pp. 263–270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Büssing, “Biological and pharmacological properties of Viscum album L,” in Mistletoe. The Genus Viscum, pp. 123–182, Harwood Academic Publishers, Amsterdam, The Netherlands, 2000. View at Google Scholar
  19. N. Hutt, M. C. Kopferschmitt-Kubler, J. Cabalion, A. Purohit, M. Alt, and G. Pauli, “Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.),” Allergologia et Immunopathologia, vol. 29, no. 5, pp. 201–203, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Steiner, “Vortrag vom 2.4,” in 1920; Geisteswissenschaft und Medizin GA 312, vol. 312, pp. 242–262, Verlag der Rudolf Steiner-NachlaBverwaltung, Dornach, Switzerland, 1961. View at Google Scholar
  21. M. Grieve, A Modern Herbal, Penguin Books, London, UK, 1994.
  22. H. Becker, “Botany of European mistletoe (Viscum album L.),” Oncology, vol. 43, no. 1, pp. 2–7, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Y. Klett and F. A. Anderer, “Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract,” Arzneimittelforschung, vol. 39, no. 12, pp. 1580–1585, 1989. View at Google Scholar · View at Scopus
  24. E. A. Mueller and F. A. Anderer, “A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon γ inducer,” Cancer Immunology Immunotherapy, vol. 32, no. 4, pp. 221–227, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. D. D. Orhan, E. Küpeli, E. Yesilada, and F. Ergun, “Anti-inflammatory and antinociceptive activity of flavonoids isolated from Viscum album ssp. album,” Zeitschrift fur Naturforschung C, vol. 61, no. 1-2, pp. 26–30, 2006. View at Google Scholar · View at Scopus
  26. K. Winkler, G. Leneweit, and R. Schubert, “Characterization of membrane vesicles in plant extracts,” Colloids and Surfaces B: Biointerfaces, vol. 45, no. 2, pp. 57–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Jäger, K. Winkler, U. Pfüller, and A. Scheffler, “Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L.,” Planta Medica, vol. 73, no. 2, pp. 157–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Kienle and H. Kiene, Die Mistel in der Onkologie: Fakten und Konzeptionelle Grundlagen, Schattauer, New York, NY, USA, 2003.
  29. A. Büssing, Mistletoe. The Genus Viscum, Hardwood Academic Publishers, Amsterdam, The Netherlands, 2000.
  30. R. K. Zee-Cheng, “Anticancer research on Loranthaceae plants,” Drugs of the Future, vol. 22, no. 5, pp. 519–530, 1997. View at Google Scholar · View at Scopus
  31. G. Bar-Sela, “White-Berry mistletoe (Viscum album L.) as complementary treatment in cancer: does it help?” European Journal of Integrative Medicine, vol. 3, no. 2, pp. e55–e62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Bussinga, K. Suzartb, J. Bergmannc, U. Pfiillefl, M. Schietzek, and K. Schweizerb, “Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins,” Cancer Letters, vol. 99, pp. 59–72, 1996. View at Publisher · View at Google Scholar
  33. T. Hajto, K. Hostanska, J. Fischer, and R. Saller, “Immunomodulatory effects of Viscum album agglutinin-I on natural immunity,” Anti-Cancer Drugs, vol. 8, no. 1, pp. S43–S46, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. I. F. Pryme, S. Bardocz, A. Pusztai, and S. W. B. Ewen, “Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins,” Histology and Histopathology, vol. 21, no. 3, pp. 285–299, 2006. View at Google Scholar · View at Scopus
  35. W. Voelter, R. Wacker, S. Stoeva, R. Tsitsilonis, and C. Betzel, “Mistletoe lectins, structure and function,” Frontiers in Natural Product Chemistry, vol. 1, no. 1, pp. 149–162, 2005. View at Publisher · View at Google Scholar
  36. Y. Endo, K. Tsurugi, and H. Franz, “The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes The RNA N-glycosidase activity of the protein,” FEBS Letters, vol. 231, no. 2, pp. 378–380, 1988. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Bantel, I. H. Engels, W. Voelter, K. Schulze-Osthoff, and S. Wesselborg, “Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis,” Cancer Research, vol. 59, no. 9, pp. 2083–2090, 1999. View at Google Scholar · View at Scopus
  38. T. Hajto, K. Hostanska, K. Weber et al., “Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo,” Natural Immunity, vol. 16, no. 1, pp. 34–46, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Lee, J. Kim, H. Kim, S. Park, and S. Lee, “Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo,” International Immunopharmacology, vol. 9, no. 13-14, pp. 1555–1561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Beuth, B. Stoffel, H. L. Ko, G. Buss, L. Tunggal, and G. Pulverer, “Immunostimulating activity of different dosages of mistletoe lectin-1 in patients with mammary carcinoma,” Arzneimittel-Forschung, vol. 45, no. 4, pp. 505–507, 1995. View at Google Scholar · View at Scopus
  41. C. Maletzki, M. Linnebacher, R. Savai, and U. Hobohm, “Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy,” Cancer Immunology, Immunotherapy, vol. 62, no. 8, pp. 1283–1292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Hong and S. Lyu, “The antimutagenic effect of mistletoe lectin (Viscum album L. var. coloratum agglutinin),” Phytotherapy Research, vol. 26, no. 5, pp. 787–790, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Bogoeva, I. Ivanov, H. Kulina, G. Russev, and L. Atanasova, “A novel cytokinin-binding property of mistletoe lectin I from viscum album,” Biotechnology and Biotechnological Equipment, vol. 27, no. 1, pp. 3583–3585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Stauder and E.-D. Kreuser, “Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research,” Onkologie, vol. 25, no. 4, pp. 374–380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Schaller and K. Urech, “Cytotoxicity of different viscotoxins and extracts from the European subspecies of Viscum album L,” Phytotherapy Research, vol. 10, pp. 473–477, 1996. View at Google Scholar
  46. J. Tabiasco, F. Pont, J. Fournié, and A. Vercellone, “Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity,” European Journal of Biochemistry, vol. 269, no. 10, pp. 2591–2600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Kuttan and R. Kuttan, “Reduction of leukopenia in mice by “Viscum album” administration during radiation and chemotherapy,” Tumori, vol. 79, no. 1, pp. 74–76, 1993. View at Google Scholar · View at Scopus
  48. H. Becker, European Mistletoe: Taxonomy, Host Trees, Parts Used, Physiology, Harwood Academic Publishers, 2000.
  49. E. Lev, M. Ephraim, and E. Ben-Arye, “European and Oriental mistletoe: From mythology to contemporary integrative cancer care,” European Journal of Integrative Medicine, vol. 3, no. 3, pp. e133–e137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Yang, M. Chen, and C. Sha, “Triterpenoids and triterpenoid saponins of Viscum liquidambaricolum,” Zhongguo Zhong Yao Za Zhi, vol. 36, no. 2, pp. 162–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. L. Zhao, X. Y. Wang, L. X. Sun, R. H. Fan, K. S. Bi, and Z. G. Yu, “Cytotoxic constituents of Viscum coloratum,” Zeitschrift fur Naturforschung C, vol. 67, no. 3-4, pp. 129–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. C. A. Pieme, J. Ngogang, and M. Costache, “In vitro antiproliferative and anti-oxidant activities of methanol extracts of Urena lobata and Viscum album against breast cancer cell lines,” Toxicological and Environmental Chemistry, vol. 94, no. 5, pp. 987–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. A. Hojjat, G. Nasrollah, and F. Ali, “Cytotoxic effects of Iranian mistletoe extract on a panel of cancer cells,” Iranian Journal of Pharmaceutical Sciences, vol. 2, no. 3, pp. 157–162, 2006. View at Google Scholar
  54. N. Dashora, V. Sodde, K. S. Prabhu, and R. Lobo, “In vitro cytotoxic activity of Dendrophthoe falcata on human breast adenocarcinoma Cells-MCF-7,” International Journal of Cancer Research, vol. 7, no. 1, pp. 47–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Johansson, J. Gullbo, P. Lindholm et al., “Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells,” Cellular and Molecular Life Sciences, vol. 60, no. 1, pp. 165–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M. R. Jacobo-Salcedo, A. Alonso-Castro, L. Salazar-Olivo et al., “Antimicrobial and cytotoxic effects of Mexican medicinal plants,” Natural Product Communications, vol. 6, no. 12, pp. 1925–1928, 2011. View at Google Scholar
  57. G. Kelter, J. M. Schierholz, I. U. Fischer, and H. Fiebig, “Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro,” Anticancer Research, vol. 27, no. 1, pp. 223–234, 2007. View at Google Scholar · View at Scopus
  58. G. Maier and H. Fiebig, “Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro,” Anti-Cancer Drugs, vol. 13, no. 4, pp. 373–379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Knöpfl-Sidler, A. Viviani, L. Rist, and A. Hensel, “Human cancer cells exhibit in vitro individual receptiveness towards different Mistletoe extracts,” Pharmazie, vol. 60, no. 6, pp. 448–454, 2005. View at Google Scholar · View at Scopus
  60. J. Beuth, H. L. Ko, H. Schneider et al., “Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model,” Anticancer Research, vol. 26, no. 6B, pp. 4451–4456, 2006. View at Google Scholar · View at Scopus
  61. F. Hugo, S. Schwitalla, B. Niggemann, K. S. Zänker, and T. Dittmar, “Viscum album extracts Iscador P and Iscador M counteract the growth factor induced effects in human follicular B-NHL cells and breast cancer cells,” Medicina, vol. 67, no. 2, pp. 90–96, 2007. View at Google Scholar · View at Scopus
  62. J. Eggenschwiler, L. von Balthazar, B. Stritt et al., “Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata),” BMC Complementary and Alternative Medicine, vol. 7, article 14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. M. Burger, U. Mengs, J. B. Schüler, and H. Fiebig, “Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro,” Arzneimittel-Forschung, vol. 51, no. 9, pp. 748–757, 2001. View at Google Scholar · View at Scopus
  64. A. M. Burger, U. Mengs, G. Kelter, J. B. Schüler, and H. Fiebig, “No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro,” Anticancer Research, vol. 23, no. 5, pp. 3801–3806, 2003. View at Google Scholar · View at Scopus
  65. F. C. S. Ramaekers, M. Harmsma, K. J. Tusenius, B. Schutte, M. Werner, and M. Ramos, “Mistletoe extracts (Viscum album L.) Iscador interact with the cell cycle machinery and target survival mechanisms in cancer cells,” Medicina, vol. 67, no. 2, pp. 79–84, 2007. View at Google Scholar · View at Scopus
  66. M. Berger and D. Schmahl, “Studies on the tumor-inhibiting efficacy of iscador in experimental animal tumors,” Journal of Cancer Research and Clinical Oncology, vol. 105, no. 3, pp. 262–265, 1983. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Drees, D. P. Berger, W. A. Dengler et al., “Direct cytotoxic effects of preparations used as unconventional methods in cancer therapy in human tumor xenografts in the clonogenic assay and in nude mice,” in Immunodeficient Animals: Models for Cancer Research, vol. 51, pp. 115–122, Karger, Basel, Switzerland, 1996. View at Google Scholar
  68. P. R. Bock, W. E. Friedel, J. Hanisch, M. Karasmann, and B. Schneider, “Efficacy and safety of long-term complementary treatment with standardized european mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma / results of a multicenter, comparative, epidemiological cohort study in Germany and Switzerland,” Arzneimittel-Forschung/Drug Research, vol. 54, no. 8, pp. 456–466, 2004. View at Google Scholar · View at Scopus
  69. B. K. Piao, Y. X. Wang, G. R. Xie et al., “Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial,” Anticancer Research, vol. 24, no. 1, pp. 303–309, 2004. View at Google Scholar · View at Scopus
  70. V. Semiglazov, V. Stepula, A. Dudov, J. Schnitker, and U. Mengs, “Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled,” Anticancer Research, vol. 26, pp. 1519–1529, 2006. View at Google Scholar
  71. J. Beuth, B. Schneider, and J. M. Schierholz, “Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative Epidemiological Cohort Study,” Anticancer Research, vol. 28, no. 1B, pp. 523–527, 2008. View at Google Scholar · View at Scopus
  72. A. Büssing, U. Bücknerb, U. Enser-Weisb et al., “Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Iscador): a randomised phase II study,” European Journal of Integrative Medicine, vol. 1, no. 1, pp. 2–3, 2008. View at Google Scholar
  73. W. Tröger, S. Jezdić, Z. Ždrale, N. Tišma, and H. J. Hamre, “Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone,” Breast Cancer, vol. 3, pp. 35–45, 2009. View at Google Scholar
  74. J. Eisenbraun, R. Scheer, M. Kröz, F. Schad, and R. Huber, “Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract,” Phytomedicine, vol. 18, no. 2-3, pp. 151–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. W. Tröger, Z. Zdrale, N. Stanković, and M. Matijašević, “Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone,” Breast Cancer, vol. 6, pp. 173–180, 2012. View at Google Scholar
  76. L. L. Anna-Maria, M. G. Velasco, and B. Reinhard, “Mistletoe treatments for minimising side effects of anticancer chemotherapy,” GMS Health Technology Assessment, vol. 2, pp. 1–8, 2006. View at Google Scholar
  77. G. S. Kienle and H. Kiene, “Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts,” European Journal of Medical Research, vol. 12, no. 3, pp. 103–119, 2007. View at Google Scholar · View at Scopus
  78. M. A. Horneber, G. Bueschel, R. Huber, K. Linde, and M. Rostock, “Mistletoe therapy in oncology,” Cochrane Database of Systematic Reviews, no. 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Ziegler and R. Grossarth-Maticek, “Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (iscador),” Evidence-Based Complementary and Alternative Medicine, vol. 7, no. 2, pp. 157–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Melzer, F. Iten, K. Hostanska, and R. Saller, “Efficacy and safety of mistletoe preparations (viscum album) for patients with cancer diseases,” Forschende Komplementarmedizin, vol. 16, no. 4, pp. 217–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. G. S. Kienle and H. Kiene, “Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies,” Integrative Cancer Therapies, vol. 9, no. 2, pp. 142–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. G. S. Kienle, F. Berrino, A. Büssing, E. Portalupi, S. Rosenzweig, and H. Kiene, “Mistletoe in cancer-a systematic review on controlled clinical trials,” European Journal of Medical Research, vol. 8, no. 3, pp. 109–119, 2003. View at Google Scholar · View at Scopus
  83. T. Ostermann, C. Raak, and A. Büssing, “Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review,” BMC Cancer, vol. 9, article 451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. G. S. Kienle, A. Glockmann, M. Schink, and H. Kiene, “Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Büssing, C. Raak, and T. Ostermann, “Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 219402, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Ostermann and A. Büssing, “Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis,” Explore, vol. 8, no. 5, pp. 277–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. U. Konrad and Z. Renatus, “Documentation of published clinical trials and observational studies with Iscador,” Tech. Rep., Verein für Krebsforschung, Arlesheim, Switzerland, 2006. View at Google Scholar
  88. J. Gutsch, H. Berger, G. Scholz, and H. Denck, “A prospective study of radically operated breast carcinoma with polychemotherapy, Helixor and untreated controls,” Deutsche Zeitschrift fur Onkologie, vol. 20, no. 4, pp. 94–101, 1988. View at Google Scholar · View at Scopus
  89. B.-M. Heiny, “Additive therapie mit standardisiertem mistelextrakt reduziert die leukopenie und verbessert die lebensqualität von patientinnen mit fortgeschrittenem mammakarzinom unter palliativer chemotherapie (VEC-Schema),” Krebsmedizin, vol. 12, pp. 1–14, 1991. View at Google Scholar
  90. E. Borrelli, “Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy,” Minerva Medica, vol. 92, pp. 105–107, 2001. View at Google Scholar
  91. R. Grossarth-Maticek, H. Kiene, S. M. Baumgartner, and R. Ziegler, “Use of iscador, an extract of European mistletoe (Viscum Album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study,” Alternative Therapies in Health and Medicine, vol. 7, no. 3, pp. 57–78, 2001. View at Google Scholar · View at Scopus
  92. M. Kröz, F. Schad, B. Matthes, H. Pickartz, and M. Girke, “Blut- und gewebseosinophilie, mistellektin-antikörper und l ebensq ualität bei einer mammakarzinom-patientin unter intratumoraler und subkutaner misteltherapie,” Forsch Komplementärmed Kl. Naturheilkd, vol. 9, pp. 160–167, 2002. View at Google Scholar
  93. K. Schumacher, B. Schneider, G. Reich et al., “Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients,” Anticancer Research, vol. 23, no. 6, pp. 5081–5087, 2003. View at Google Scholar · View at Scopus
  94. V. F. Semiglasov, V. V. Stepula, A. Dudov, W. Lehmacher, and U. Mengs, “The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial,” Anticancer Research, vol. 24, no. 2, pp. 1293–1302, 2004. View at Google Scholar · View at Scopus
  95. L. Auerbach, V. Dostal, I. Václavik-Fleck et al., “Signifikant höherer a nteil aktivierter NK-Zellen durch additive mistel therapie bei chemotherapierten mamma-ca-Patientinnen in einer prospektiv randomisierten doppelblinden studie,” in Fortschritte in der Misteltherapie, R. Scheer, R. Bauer, H. Becker, V. Fintelmann, F. Kemper, and H. Schilcher, Eds., pp. 543–554, KVC, Essen, Germany, 2005. View at Google Scholar
  96. R. Grossarth-Maticek and R. Ziegler, “Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador),” Forschende Komplementarmedizin, vol. 13, no. 5, pp. 285–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Loewe-Mesch, J. J. Kuehn, K. Borho et al., “Adjuvant simultaneous treatment with mistletoe during chemotherapy for breast cancer—influence on immune parameters, quality of life and tolerability,” Forschende Komplementarmedizin, vol. 15, no. 1, pp. 22–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Wode, T. Schneider, I. Lundberg, and G. S. Kienle, “Mistletoe treatment in cancer-related fatigue: a case report,” Cases Journal, vol. 2, no. 1, article 77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Tröger, “Connection between quality of life and neutropenia in breast cancer patients who were solely treated with chemotherapy or additionally with mistletoe therapy: results of a randomized study,” Deutsche Zeitschrift fur Onkologie, vol. 43, no. 2, pp. 58–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Werner, P. R. Bock, J. Hanisch, and G. Stauder, “Supportive therapy with mistletoe extract in tumor patients, results of four controlled pharmacoepidemiological cohort studies as basis for prospective studies (clinical report),” Phytomedicine, vol. 18, no. 1, pp. S12–S13, 2011. View at Google Scholar
  101. M. Brandenberger, A. P. Simões-Wüst, M. Rostock, L. Rist, and R. Saller, “An exploratory study on the quality of life and individual coping of cancer patients during mistletoe therapy,” Integrative Cancer Therapies, vol. 11, no. 2, pp. 90–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. W. Tröger, Z. Zdrale, N. Tišma, and M. Matijašević, “Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 430518, 9 pages, 2014. View at Publisher · View at Google Scholar
  103. T. J. Yoon, Y. C. Yoo, T. B. Kang et al., “Lectins isolated from Korean mistletoe (Viscum album coloratum) induce apoptosis in tumor cells,” Cancer Letters, vol. 136, no. 1, pp. 33–40, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Harmsma, M. Ummelen, W. Dignef, K. J. Tusenius, and F. C. S. Ramaekers, “Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells,” Drug Research, vol. 56, no. 6, pp. 474–482, 2006. View at Google Scholar · View at Scopus
  105. A. Büssing, “Immune modulation using mistletoe (Viscum album L.) extracts Iscador,” Arzneimittelforschung, vol. 56, no. 6, pp. 508–515, 2006. View at Google Scholar
  106. T. Hajto, “Immunomodulatory effects of iscador: a Viscum album preparation,” Oncology, vol. 43, no. 1, pp. 51–65, 1986. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Beuth, H. L. Ko, H. Gabius, H. Burrichter, K. Oette, and G. Pulverer, “Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients,” Clinical Investigator, vol. 70, no. 8, pp. 658–661, 1992. View at Google Scholar · View at Scopus
  108. J. Beuth, H. L. Ko, L. Tunggal, J. Geisel, and G. Pulverer, “Comparative studies on the immunoactive potency of galactoside-specific lectin from mistletoe/pure substance against standardized extract,” Drug Research, vol. 43, no. 2, pp. 166–169, 1993. View at Google Scholar · View at Scopus
  109. J. Beuth, H.-J. Gabius, M. K. Steuer, J. Geisel, H. L. Ko, and G. Pulverer, “Influence of mistletoe lectin administration on defined acute phase reactants in cancer patients,” Medizinische Klinik, vol. 88, no. 5, pp. 287–290, 1993. View at Google Scholar · View at Scopus
  110. B.-M. Heiny and J. Beuth, “Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients,” Anticancer Research, vol. 14, no. 3B, pp. 1339–1342, 1994. View at Google Scholar · View at Scopus
  111. B. M. Heiny, V. Albrecht, and J. Beuth, “Correlation of immune cell activities and β-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract,” Anticancer Research, vol. 18, no. 1, pp. 583–586, 1998. View at Google Scholar · View at Scopus
  112. H. O. Pae, W. G. Seo, G. S. Oh et al., “Potentiation of tumor necrosis factor-α-induced apoptosis by mistletoe lectin,” Immunopharmacology and Immunotoxicology, vol. 22, no. 4, pp. 697–709, 2000. View at Publisher · View at Google Scholar · View at Scopus
  113. E. Kovacs, “Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract,” Biomedicine and Pharmacotherapy, vol. 54, no. 6, pp. 305–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Büssing, M. Bischof, W. Hatzmann et al., “Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients,” Anticancer Research C, vol. 25, no. 6, pp. 4753–4757, 2005. View at Google Scholar · View at Scopus
  115. A. Büssing, C. Stumpf, W. Tröger, and M. Schietzel, “Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts,” Anticancer Research, vol. 27, no. 4, pp. 2903–2910, 2007. View at Google Scholar · View at Scopus
  116. A. Büssing, W. Tröger, C. Stumpf, and M. Schietzel, “Local reactions to treatments with viscum album L. extracts and their association with T-lymphocyte subsets and quality of life,” Anticancer Research, vol. 28, no. 3, pp. 1893–1897, 2008. View at Google Scholar · View at Scopus
  117. L. Heinzerling, V. von Baehr, C. Liebenthal, R. von Baehr, and H. Volk, “Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo,” Journal of Clinical Immunology, vol. 26, no. 4, pp. 347–359, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. N. E. Gardin, “Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series,” Phytotherapy Research, vol. 23, no. 3, pp. 407–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. G. S. Son, W. S. Ryu, H. Y. Kim, S. U. Woo, K. H. Park, and J. W. Bae, “Immunologic response to mistletoe extract (Viscum album L.) after conventional treatment in patients with operable breast cancer,” Journal of Breast Cancer, vol. 13, no. 1, pp. 14–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. C. Hagens, T. Giese, A. Staudt et al., “Does a treatment with Viscum album (Iscador [R] P) in patients with breast cancer influence the expression of the T-cell receptor (TCR)-zeta chains of T - and NK-cells?(Report),” Phytomedicine, vol. 18, p. S24, 2011. View at Google Scholar